Stock Watch: Biotech’s Commercial Laggards Drag On Sector
Biotech Companies Can Remain Unprofitable Years After Product Launches
Some commercial-stage biotechnology companies blame the pandemic for their declining sales and continued losses. While an acquisition by a bigger company might once have been an aspiration, further fundraisings seem to be the more likely outcome.
You may also be interested in...
Do rare disease drugs with tiny patient populations lie outside the profitability continuum that runs from small-molecule primary care products to specialist biologics?
A post-pandemic rebound in oncology sales contrasts with the lagging revenues of drugs administered by primary care and office-based specialists. Declining COVID-19 vaccine, diagnostic and treatment revenues could add further volatility.
Improving efficacy by combining drugs has been a mainstay of cancer therapy but adding new targeted drugs together based on very early-stage data is not working out, especially when one of the drugs is barely active on its own.